



THE HOUSE OF REPRESENTATIVES

STANDING COMMITTEE ON HEALTH, AGED CARE AND SPORT

Inquiry into approval processes for new drugs and novel medical technologies in Australia

**PUBLIC HEARING
Friday 12 March 2021**

**Corinthian Room
Sydney Masonic Centre, 66 Goulburn Street, Sydney**

Time	Witness
9.40 am	Pfizer Australia and New Zealand Ms Louise Graham, Director, Head of Market Access Ms Anne Harris, Country Manager Merck Healthcare Pty Ltd Ms Leah Goodman, Managing Director Australia and New Zealand Biogen Australia and New Zealand Dr Kylie Bromley, Managing Director
10.40 am	MSD Australia and New Zealand Mr Michael Azrak, Managing Director Amgen Mr Ian Noble, Director, Value, Access & Policy AbbVie Mr Chris Stemple, Vice President and General Manager, Australia and New Zealand Novartis Pharmaceuticals Australia and New Zealand Mr Richard Tew, Country President and Pharma Country Head
11.40 am	Sydney Children's Hospitals Network and Children's Medical Research Institute Prof Ian Alexander, Head, Gene Therapy Research Unit Kids Research, the Sydney Children's Hospital Network Dr Wendy Gold, Chair Gene Therapy Advisory Steering group & Head of Molecular Neurobiology Research Group
12.40 pm	Lunch break

1.30 pm	<p>BXTAccelyon Australia Pty Ltd Mrs Nicola Leavold, Commercial Director</p> <p>Medtronic Australasia Ms Liz Carnabuci, Vice President & Managing Director, ANZ</p> <p>BIOTRONIK Australia Pty Ltd Ms Jan Ewert, Managing Director</p> <p>Edwards Lifesciences, ANZ & Korea Mr Pat Williams, Managing Director</p> <p>Stryker Mr Maurice Ben-Mayor, President</p>
2.45 pm	<p>Maridulu Budyari Gumal, The Sydney Partnership for Health, Education, Research and Enterprise (SPHERE) Dr Peter Spencer, Medtech Innovation Advisor and HealthHatchery Co-founder Rowena Tucker, Interim Executive Director</p>
3.30 pm	Close